Abstract Library

#4537 The usefulness of circulating fibrosis markers in detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a potential serious fibrotic complication in patients with neuroendocrine neoplasms (NENs), affecting the heart valves. Early detection is crucial to avoid severe manifestations. NT-proBNP is suggested as an initial screening tool in detection of CHD; however, the value of NT-proBNP as a screening tool is questionable.

Conference:

Presenting Author: Lau T

Authors: Lau T, Angeli E, Oksjoki R, Rasmussen V, Genovese F,

Keywords: carcinoid heart disease, biomarker, fibrosis marker,

#4110 The role of fibrosis markers in predicting decline in renal function in patients undergoing PRRT

Introduction: Renal impairment due to renal fibrosis is a potential side effect in NET-patients undergoing Peptide Receptor Radionuclide Therapy (PRRT). Fibrosis markers are small collagen formation - and degradation fragments that are measurable in circulation at very early stages of fibrosis formation.

Conference:

Presenting Author: Lau T

Authors: Lau T, Bossen L, Rasmussen D, Karsdal M, Genovese F,

Keywords: PRRT, Biomarker, Fibrosis Marker,

#1886 Effect of Treatment with Prolonged-Release Somatostatin Analogues on the Concentration of Serum Fibrosis Markers in Patients with Carcinoid Syndrome.

Introduction: A fibrosis is a major local and/or distant complication of neuroendocrine tumours (NETs) of the small intestine secreting serotonin. Tumour cells produce connective tissue growth factor CTGF and transforming growth factor TGFα and TGFβ which locally stimulate fibrosis and cause distant fibrosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Foltyn W, Zemczak A, Rosiek V, Kilian-Kita A, Kos-Kudła B,

Keywords: fibrosis,CTGF,TGFβ,carcinoid syndrome,